Cue Biopharma, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cue Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • Cue Biopharma, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 72.5 %, a 50.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 72.5 +24.3 +50.2% Jun 30, 2024
Q1 2024 65.3 +20.9 +46.9% Mar 31, 2024
Q4 2023 57.8 +15.4 +36.3% Dec 31, 2023
Q3 2023 50.5 +11.2 +28.6% Sep 30, 2023
Q2 2023 48.3 +15 +45.1% Jun 30, 2023
Q1 2023 44.5 +15.9 +55.8% Mar 31, 2023
Q4 2022 42.4 +17 +66.8% Dec 31, 2022
Q3 2022 39.3 +14.1 +55.8% Sep 30, 2022
Q2 2022 33.3 +8.83 +36.1% Jun 30, 2022
Q1 2022 28.5 +3.26 +12.9% Mar 31, 2022
Q4 2021 25.4 -0.71 -2.72% Dec 31, 2021
Q3 2021 25.2 -1.98 -7.29% Sep 30, 2021
Q2 2021 24.4 -10.3 -29.6% Jun 30, 2021
Q1 2021 25.3 -23.7 -48.4% Mar 31, 2021
Q4 2020 26.1 -34.8 -57.1% Dec 31, 2020
Q3 2020 27.2 -40.3 -59.7% Sep 30, 2020
Q2 2020 34.7 -14.7 -29.8% Jun 30, 2020
Q1 2020 49 +21.2 +76.5% Mar 31, 2020
Q4 2019 60.9 +47.1 +342% Dec 31, 2019
Q3 2019 67.5 +58.5 +650% Sep 30, 2019
Q2 2019 49.4 Jun 30, 2019
Q1 2019 27.8 Mar 31, 2019
Q4 2018 13.8 Dec 31, 2018
Q3 2018 9 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.